NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 04:00PM ET
6.84
Dollar change
-0.04
Percentage change
-0.58
%
IndexRUT P/E- EPS (ttm)-0.07 Insider Own11.36% Shs Outstand53.98M Perf Week-4.87%
Market Cap369.22M Forward P/E- EPS next Y-1.23 Insider Trans-0.01% Shs Float47.85M Perf Month-0.51%
Enterprise Value150.73M PEG- EPS next Q-0.29 Inst Own85.60% Short Float12.16% Perf Quarter137.50%
Income-0.51M P/S4.62 EPS this Y-630.36% Inst Trans-1.40% Short Ratio9.91 Perf Half Y41.32%
Sales80.00M P/B1.62 EPS next Y-5.26% ROA-0.21% Short Interest5.82M Perf YTD45.53%
Book/sh4.23 P/C1.63 EPS next 5Y- ROE-0.23% 52W High10.13 -32.48% Perf Year8.92%
Cash/sh4.20 P/FCF48.84 EPS past 3/5Y59.06% 54.59% ROIC-0.22% 52W Low2.32 195.46% Perf 3Y33.07%
Dividend Est.- EV/EBITDA- Sales past 3/5Y61.02% - Gross Margin98.10% Volatility7.53% 6.73% Perf 5Y-67.52%
Dividend TTM- EV/Sales1.88 EPS Y/Y TTM97.11% Oper. Margin-13.00% ATR (14)0.50 Perf 10Y-
Dividend Ex-Date- Quick Ratio28.71 Sales Y/Y TTM3087.25% Profit Margin-0.64% RSI (14)53.21 Recom2.00
Dividend Gr. 3/5Y- - Current Ratio28.71 EPS Q/Q34.81% SMA20-1.73% Beta2.37 Target Price8.14
Payout- Debt/Eq0.04 Sales Q/Q- SMA5013.27% Rel Volume1.48 Prev Close6.88
Employees45 LT Debt/Eq0.03 EarningsMay 01 BMO SMA20062.92% Avg Volume587.11K Price6.84
IPOJul 18, 2019 Option/ShortYes / Yes EPS/Sales Surpr.4.76% - Trades Volume871,421 Change-0.58%
Date Action Analyst Rating Change Price Target Change
May-23-25Upgrade Leerink Partners Market Perform → Outperform $12
May-15-25Upgrade Cantor Fitzgerald Neutral → Overweight $10
Sep-13-24Downgrade H.C. Wainwright Buy → Neutral $17 → $4
Sep-12-24Downgrade Stifel Buy → Hold
Sep-12-24Downgrade RBC Capital Mkts Outperform → Sector Perform $15 → $4
Sep-12-24Downgrade Leerink Partners Outperform → Market Perform $4
Sep-12-24Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-12-24Downgrade BofA Securities Neutral → Underperform $10 → $2
Sep-09-24Upgrade BofA Securities Underperform → Neutral $5 → $10
May-20-24Initiated Cantor Fitzgerald Overweight $23
Jun-06-25 04:30PM
May-30-25 01:17AM
May-29-25 04:10PM
08:30AM
May-09-25 04:30PM
04:05PM Loading…
May-08-25 04:05PM
May-02-25 03:03AM
01:27AM
May-01-25 01:55PM
07:00AM
Apr-24-25 08:00AM
Apr-11-25 04:30PM
Mar-26-25 10:17AM
Mar-04-25 04:05PM
Feb-26-25 02:04AM
01:28AM Loading…
01:28AM
Feb-25-25 07:00AM
01:52AM
Feb-18-25 04:05PM
Feb-07-25 04:30PM
Feb-06-25 04:05PM
Nov-28-24 12:00PM
Nov-26-24 04:05PM
Nov-14-24 02:07AM
Nov-13-24 07:00AM
Nov-12-24 04:05PM
Nov-06-24 08:00AM
Oct-18-24 08:00AM
Oct-11-24 04:30PM
Oct-09-24 03:30PM
03:02PM Loading…
Oct-07-24 03:02PM
Oct-04-24 09:35AM
Sep-17-24 01:30AM
Sep-16-24 09:35AM
Sep-13-24 04:30PM
Sep-12-24 11:32AM
08:10AM
06:55AM
Sep-09-24 02:28PM
Aug-27-24 04:05PM
Aug-23-24 04:30PM
Aug-21-24 09:55AM
Aug-19-24 07:00AM
Aug-09-24 04:30PM
Aug-05-24 12:00PM
12:00PM
09:55AM
Jul-31-24 07:00AM
Jul-24-24 08:00AM
Jun-12-24 08:00AM
Jun-06-24 08:00AM
May-26-24 09:02AM
May-20-24 07:55AM
May-15-24 09:55AM
May-14-24 08:55AM
07:49AM
03:01AM
May-13-24 11:53AM
11:02AM
08:45AM
08:32AM
07:47AM
07:23AM
07:00AM
06:00AM
May-09-24 08:00AM
May-08-24 08:00AM
May-06-24 08:00AM
Mar-28-24 04:05PM
Mar-22-24 04:30PM
Mar-18-24 07:00AM
Mar-08-24 04:30PM
Mar-05-24 08:00AM
Feb-28-24 09:35AM
Feb-27-24 09:23PM
08:10AM
07:35AM
07:00AM
Feb-20-24 04:01PM
Feb-06-24 08:00AM
Dec-07-23 04:30PM
Nov-10-23 04:30PM
Nov-09-23 08:00AM
Nov-08-23 03:43PM
Nov-07-23 08:03AM
07:00AM
Oct-31-23 08:50AM
Sep-22-23 08:00AM
Sep-15-23 04:30PM
Sep-07-23 08:00AM
Aug-25-23 09:16AM
Aug-24-23 10:15AM
08:42AM
01:35AM
Aug-22-23 02:02PM
11:39AM
07:00AM
Aug-11-23 04:53PM
Aug-03-23 08:15AM
07:01AM
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tourangeau GregPrincipal Accounting OfficerMay 08 '25Sale5.064982,52014,062May 09 04:15 PM
Sapir AlexSee RemarksJul 03 '24Option Exercise3.27150,000490,500193,360Jul 08 08:00 AM